Home Newsfeeds Merrimack Pharmaceuticals Q3 EPS $(0.03) Up From $(0.04) YoY

Merrimack Pharmaceuticals Q3 EPS $(0.03) Up From $(0.04) YoY

Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly earnings of $(0.03) per share. This is a 175 percent increase over losses of $(0.04) per share from the same period last year.

byBenzinga Newsdesk

November 3, 2022

1 minute read

Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly earnings of $(0.03) per share. This is a 175 percent increase over losses of $(0.04) per share from the same period last year.

United Airlines to Outperform US Peers in Medium Term: Analysts Lift Expectations

By Anusuya Lahiri

July 21, 2:43 PM

Raymond James analyst Savanthi Syth maintained United Airlines Holdings Inc (NASDAQ: UAL) with an Outperform and raised the price

UAL

Mainz Biomed And TestDNA Drive CRC Innovation At The 10th Gdańsk Gastroenterology Symposium On January 12th–13th, 2024 To Discuss Colorectal Cancer – The Need For Earlier Detection

By Benzinga Newsdesk

January 11, 9:05 AM

https://www.eqs-news.com/news/corporate/mainz-biomed-and-testdna-drive-crc-innovation-at-the-10th-gdansk-gastroenterology-symposium/1975437Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology

MYNZ